BPTH Stock Overview
Operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Bio-Path Holdings, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.82 |
| 52 Week High | US$12.37 |
| 52 Week Low | US$0.61 |
| Beta | 0.22 |
| 11 Month Change | -23.36% |
| 3 Month Change | -31.67% |
| 1 Year Change | -91.51% |
| 33 Year Change | -99.04% |
| 5 Year Change | -99.43% |
| Change since IPO | -99.97% |
Recent News & Updates
Recent updates
We're Keeping An Eye On Bio-Path Holdings' (NASDAQ:BPTH) Cash Burn Rate
Nov 05
Bio-Path GAAP EPS of -$0.42 beats by $0.07
Aug 16Is Bio-Path Holdings (NASDAQ:BPTH) In A Good Position To Deliver On Growth Plans?
Jul 08Here's Why We're Not Too Worried About Bio-Path Holdings' (NASDAQ:BPTH) Cash Burn Situation
Mar 24Bio-Path Holdings (NASDAQ:BPTH) Is In A Good Position To Deliver On Growth Plans
Aug 17We Think Bio-Path Holdings (NASDAQ:BPTH) Needs To Drive Business Growth Carefully
Mar 26Will Bio-Path Holdings (NASDAQ:BPTH) Spend Its Cash Wisely?
Dec 11Dosing underway in Bio-Path's early-stage BP1002 study
Nov 19Bio-Path EPS beats by $0.07
Nov 13Shareholder Returns
| BPTH | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0.9% | 2.4% | 2.2% |
| 1Y | -91.5% | 16.2% | 31.7% |
Return vs Industry: BPTH underperformed the US Biotechs industry which returned 15.2% over the past year.
Return vs Market: BPTH underperformed the US Market which returned 31.1% over the past year.
Price Volatility
| BPTH volatility | |
|---|---|
| BPTH Average Weekly Movement | 15.2% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: BPTH's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: BPTH's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 10 | Peter Nielsen | www.biopathholdings.com |
Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome.
Bio-Path Holdings, Inc. Fundamentals Summary
| BPTH fundamental statistics | |
|---|---|
| Market cap | US$3.44m |
| Earnings (TTM) | -US$10.51m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.3x
P/E RatioIs BPTH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BPTH income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$10.51m |
| Earnings | -US$10.51m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.44 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did BPTH perform over the long term?
See historical performance and comparison